Bio Plus Co., Ltd (KOSDAQ: 099430)

Market Cap	425.08B
Revenue (ttm)	53.48B
Net Income (ttm)	17.80B
Shares Out	56.30M
EPS (ttm)	304.95
PE Ratio	24.76
Forward PE	n/a
Dividend	70.00 (0.93%)
Ex-Dividend Date	Dec 27, 2024

Volume	847,441
Open	7,550.00
Previous Close	7,570.00
Day's Range	7,470.00 - 7,830.00
52-Week Range	4,250.00 - 8,000.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 12, 2025

About Bio Plus

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; S...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2003
• Employees: 102
• Stock Exchange: KOSDAQ
• Ticker Symbol: 099430

Financial Performance

In 2023, Bio Plus's revenue was 65.04 billion, an increase of 14.68% compared to the previous year's 56.72 billion. Earnings were 25.58 billion, an increase of 21.02%.